| APITOPE TECHNOLOGY (BRISTOL) LIMITED Patent applications |
| Patent application number | Title | Published |
|---|
| 20120121625 | PEPTIDE - The present invention provides peptides at least partly derivable from FVIII which are capable of binding to an MHC class II molecule without further antigen processing and being recognised by a factor VIII specific T cell. In particular, the present invention provides a peptide comprising or consisting of the sequence EDNIMVTFRNQASR. The present invention also relates to the use of such a peptide for the prevention or suppression of inhibitor antibody formation in haemophilia A and/or acquired haemophilia. | 05-17-2012 |
| 20100286054 | Composition - The present invention relates to a composition which comprises the following myelin basic protein peptides: MBP 30-44, MBP 83-99, MBP 131-145, and MBP 140-154. The composition may be used to treat a disease, in particular multiple sclerosis and/or optical neuritis and the invention also relates to such uses and methods. | 11-11-2010 |
| 20100129853 | DISEASE MARKERS - The present invention relates to biomarkers for autoimmune disease, and in particular to a method for determining a status of an autoimmune disease in a test subject, comprising measuring production of IL-5 and IL-13, as well as to associated uses and kits. | 05-27-2010 |
